Corticosterone increases the number of CREB1 binding sites and CREB1 binding intensity. (A) Nascent RNA levels of Ppargc1a in primary hepatocytes following 1, 3, and 8 h of treatment with different combinations of glucagon (gluc) and corticosterone (cort): (*) statistical significance (P ≤ 0.05) compared to a nontreated sample (NT) in each time point. (B) Genome browser tracks of the Tat locus depicting increases in CREB1 binding following glucagon treatment (1 h) and cotreatment with corticosterone (1 h) as well as increased accessibility following either fasting or GR activation by dexamethasone (dex). Adrenalectomized mice were treated with dex (1 mg/kg) for 1 h, DNase-seq data were generated and described in Grøntved et al. (2013). (C,D) Cotreatment with glucagon and corticosterone leads to an increase in the number (C) and intensity (D) of CREB1 binding sites. (E,F) Corticosterone-increased CREB1 binding sites show more CREB1 binding than corticosterone-unaffected sites (measured by ChIP-seq tag density). (**) Statistical significance (P ≤ 0.0001).
